RDInvesting Provides Investors with Free In-Depth Equity Reports on ADHD, CCXI, FLEX and NTAPadmin
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Alcobra Ltd. (NASDAQ: ADHD) shares declined 0.47 percent to close at $16.98 a share Wednesday. The stock traded between $16.70 and $18.45 on volume of 165,796 shares traded. Analysts at Stifel have recently initiated with a “buy” rating. Shares of Alcobra have gained approximately 125.0 percent year-to-date.
Find out more about Alcobra including full access to the free equity report at:
ChemoCentryx Inc. (NASDAQ: CCXI) shares gained 2.79 percent to close at $5.16 a share Wednesday. The stock traded between $5.11 and $5.38 on volume of 1.84 million shares traded. Analysts at Citigroup have recently downgraded the company’s rating to “neutral” from “buy”. Shares of ChemoCentryx have declined approximately 53.0 percent year-to-date.
Find out more about ChemoCentryx including full access to the free equity report at:
Flextronics International Ltd. (NASDAQ: FLEX) shares declined 1.61 percent to close at $7.33 a share Wednesday. The stock traded between $7.19 and $7.42 on volume of 5.87 million shares traded. Analysts at Goldman Sachs have recently downgraded the company’s rating to “sell” from “neutral”. Shares of Flextronics International have gained approximately 18.0 percent year-to-date.
Find out more about Johnson Controls including full access to the free equity report at:
NetApp Inc. (NASDAQ: NTAP) shares declined 0.17 percent to close at $40.67 a share Wednesday. The stock traded between $39.73 and $40.89 on volume of 4.05 million shares traded. Analysts at Morgan Stanley have recently downgraded the company’s rating to “equal weight” from “overweight”. Shares of NetApp have gained approximately 20.0 percent year-to-date.
Find out more about NetApp including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Posted: December 5th, 2013 under ACCESSWIRE.